Welcome to our dedicated page for Rapid Micro Biosystems SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When you follow Rapid Micro Biosystems (RPID), you鈥檙e not just tracking another life-sciences company鈥攜ou鈥檙e monitoring how quickly the pharmaceutical world adopts automated microbial quality control. Investors typically open a filing searching for answers like 鈥淲here can I find Rapid Micro Biosystems鈥� quarterly earnings report 10-Q filing?鈥� or 鈥淲hat do Rapid Micro Biosystems insider trading Form 4 transactions reveal about Growth Direct demand?鈥� We bring every disclosure into one streamlined view.
Stock Titan鈥檚 AI reads each 10-K, 10-Q, 8-K and immediately highlights the numbers that matter: unit placements, consumables revenue, R&D outlays, and regulatory commentary. Instead of wading through dense technical language, you鈥檒l see concise plain-English explanations鈥攑erfect for anyone Googling 鈥淩apid Micro Biosystems SEC filings explained simply鈥� or 鈥渦nderstanding Rapid Micro Biosystems SEC documents with AI.鈥�
Need specific data fast? Use our real-time alerts for Rapid Micro Biosystems Form 4 insider transactions: the moment an executive buys or sells, you鈥檒l receive context and trend analysis. Our coverage also includes:
- 10-K annual report sections on market adoption, simplified for quick scans鈥攊deal for 鈥淩apid Micro Biosystems annual report 10-K simplified鈥� queries.
- 10-Q earnings report breakouts of consumable gross margin鈥攁nswering searches for 鈥淩apid Micro Biosystems earnings report filing analysis.鈥�
- 8-K material events explained in minutes, from FDA updates to major customer wins.
- Proxy statement executive compensation summaries, tying pay packages to Growth Direct milestones.
With comprehensive coverage, real-time EDGAR updates, and AI-powered summaries, our filings hub turns Rapid Micro Biosystems鈥� complex disclosures into practical insights you can act on today.
Rapid Micro Biosystems reported total revenue of $7.262 million for the quarter and $14.467 million for the six months ended June 30, 2025, up from $6.618 million and $12.229 million in the comparable prior periods. The company recorded a net loss of $11.858 million for the quarter and $23.121 million year-to-date, narrowing from prior-year losses. Cash and cash equivalents were $18.333 million and short-term investments were $12.922 million, with total current assets of $60.146 million.
The company disclosed a material financing arrangement: a $45.0 million loan facility with Trinity Capital as agent, of which an initial $20.0 million tranche was drawn. Management states existing cash, investments and the initial draw from the facility are expected to fund operations for at least twelve months. The report highlights ongoing operating losses, inventory reserves, concentration among certain customers, and stock-based compensation trends.
Rapid Micro Biosystems secured a multi-tranche term loan facility of up to $45.0 million, drawing $20.0 million at closing. The facility is structured in four tranches with additional amounts available when commercial and operational milestones are met and includes a lender option tranche of $5.0 million. Loans are secured by a first-priority lien on substantially all assets of the company and may be guaranteed by subsidiaries.
Interest is floating with an initial rate of 11.5% per annum (floor 11.0%), a 36-month interest-only period followed by amortization, and a maturity date of September 1, 2030. Fees include a 1.0% commitment fee on amounts drawn, prepayment premiums (3.0% year one, 2.0 year two, 1.0% thereafter), and a 4.0% end-of-term payment on amounts drawn. Each draw requires issuance of warrants equal to 3.0% of the drawn amount (cashless exercise, ten-year term); the company issued warrants for up to 179,104 shares at a $3.35 exercise price for the first tranche. The agreement contains customary covenants and defaults but does not require maintaining specific revenue or cash thresholds.
Rapid Micro Biosystems, Inc. (symbol: RPID) has filed a Form 144 disclosing an insider鈥檚 intent to sell shares. Robert G. Spignesi plans to dispose of 11,874 Class A shares on or about 11 July 2025 via NASDAQ, using Fidelity Brokerage Services as broker. At the reference price in the notice, the sale is valued at roughly $39,498.86. The filing cites the shares as recently vested restricted stock received as compensation on 10 July 2025.
The document also lists three prior transactions by the same insider between 8-10 July 2025 totaling 33,688 shares for gross proceeds of $116,981.01. With 39,332,172 shares outstanding, the forthcoming sale represents about 0.03 % of the company鈥檚 float, indicating a routine liquidity event rather than a material ownership change.
FAQ
What is the current stock price of Rapid Micro Biosystems (RPID)?
What is the market cap of Rapid Micro Biosystems (RPID)?
